# Phase 2 Neuroendocrine Tumors trials recruiting: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Neuroendocrine Tumors that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Neuroendocrine Tumors trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/neuroendocrine-tumors

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946627 | Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neuroendocrine Tumors, Liver Metastases | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946627) |
| July 29, 2026 | NCT07733024 | Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroendocrine Tumors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733024) |
| July 6, 2026 | NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | Compass Therapeutics | Phase 2 | Recruiting | Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684170) |
| February 11, 2026 | NCT07404176 | Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors | Tata Memorial Hospital | Phase 2 | Recruiting | Neuroendocrine Neoplasms (Tumours), Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07404176) |
| September 3, 2025 | NCT07151391 | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) | University of Utah | Phase 2 | Recruiting | Neuroendocrine Tumors, Gynecologic Cancer | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07151391) |
| April 14, 2025 | NCT06926634 | Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) | Washington University School of Medicine | Phase 2 | Recruiting | High Grade Neuroendocrine Neoplasms | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926634) |
| January 8, 2025 | NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | Beijing Chest Hospital | Phase 2 | Not yet recruiting | Neuroendocrine Tumors | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764368) |
| June 25, 2024 | NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors | AC Camargo Cancer Center | Phase 2 | Recruiting | Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06472388) |
| May 9, 2024 | NCT06406465 | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | National Cancer Institute (NCI) | Phase 2 | Recruiting | Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06406465) |
| May 2, 2024 | NCT06395402 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry | University of Iowa | Phase 2 | Recruiting | Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2 | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395402) |
| April 3, 2024 | NCT06345079 | Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | Australasian Gastro-Intestinal Trials Group | Phase 2 | Recruiting | Neuroendocrine Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06345079) |
| September 21, 2023 | NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | Recruiting | Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045260) |
| February 27, 2023 | NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | University of California, San Francisco | Phase 2 | Recruiting | Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05746208) |
| September 26, 2022 | NCT05554003 | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs)... | European Institute of Oncology | Phase 2 | Recruiting | Neuroendocrine Tumors, Frailty, Chemotherapy Effect | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05554003) |
| August 15, 2022 | NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring | Centre Oscar Lambret | Phase 2 | Recruiting | Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors... | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05500391) |
| March 2, 2022 | NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | Fox Chase Cancer Center | Phase 2 | Recruiting | Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05263050) |
| December 21, 2021 | NCT05165407 | Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) | Peking University | Phase 2 | Recruiting | Neuroendocrine Neoplasm | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05165407) |
| July 8, 2021 | NCT04954820 | Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 | Recruiting | Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04954820) |
| June 8, 2021 | NCT04917484 | Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroendocrine Neoplasm | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04917484) |
| May 17, 2021 | NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors | Charite University, Berlin, Germany | Phase 2 | Not yet recruiting | Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer, Sarcoma, Rectal Cancer, Neuroendocrine Tumors... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04889742) |
| May 17, 2021 | NCT04888481 | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors | University of Alberta | Phase 2 | Recruiting | Neuroendocrine Tumors | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04888481) |
| April 8, 2021 | NCT04837885 | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases | University Hospital, Bordeaux | Phase 2 | Recruiting | Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04837885) |
| April 8, 2020 | NCT04339036 | CapTemY90 for Grade 2/3 NET Liver Metastases | Abramson Cancer Center at Penn Medicine | Phase 2 | Recruiting | Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04339036) |
| November 18, 2019 | NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | Recruiting | Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, Vaccination | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04166006) |
| August 29, 2019 | NCT04074135 | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | National Cancer Institute (NCI) | Phase 2 | Recruiting | VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors | 740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04074135) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2 |
| European Institute of Oncology | 1 |
| University of Sao Paulo | 1 |
| University of Alberta | 1 |
| Centre Oscar Lambret | 1 |
| Beijing Chest Hospital | 1 |
| Australasian Gastro-Intestinal Trials Group | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| University Hospital, Bordeaux | 1 |
| University of California, San Francisco | 1 |
| Peking University | 1 |
| University of Utah | 1 |
| Tata Memorial Hospital | 1 |
| University of Iowa | 1 |
| Washington University School of Medicine | 1 |
| Compass Therapeutics | 1 |
| Institut du Cancer de Montpellier - Val d'Aurelle | 1 |
| Fox Chase Cancer Center | 1 |
| AC Camargo Cancer Center | 1 |
| Charite University, Berlin, Germany | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 12 |
| Italy | 3 |
| France | 3 |
| China | 2 |
| Brazil | 2 |
| Canada | 2 |
| Australia | 1 |
| Denmark | 1 |
| India | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Geological services in the United States](https://specstream.ai/data/businesses/geological-services/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Hematology practices in the United States](https://specstream.ai/data/businesses/hematology-practices/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
